BRCA2 and breast cancer: In fact, the subject III.6, a maternal proband’s cousin diagnosed with a metastatic ovarian cancer at the age of 53 and for whom the analysis was performed on formalin-fixed-paraffin-embedded (FFPE) tissue, carried the BRCA1 c.5095C>T variant in heterozygous status while the III.1 subject, a paternal cousin with a diagnosis of breast cancer at the age of 47, resulted positive for the BRCA2 small deleterious variant.